

Cristiano Noto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3691711/publications.pdf>

Version: 2024-02-01

75
papers

2,812
citations

279798
23
h-index

214800
47
g-index

83
all docs

83
docs citations

83
times ranked

3548
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
2	The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 134-144.	4.8	137
3	Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia. <i>Scientific Reports</i> , 2016, 6, 38897.	3.3	135
4	The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. <i>Molecular Neurobiology</i> , 2020, 57, 778-797.	4.0	93
5	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1376-1382.	3.1	84
6	Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu042-pyu042.	2.1	77
7	High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 422-429.	2.6	69
8	Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 416-431.	0.7	67
9	Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 168-176.	1.7	61
10	Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Na ⁺ -ve First Episode Psychosis. <i>Molecular Neurobiology</i> , 2016, 53, 5701-5709.	4.0	59
11	Oxidative stress in drug na ⁺ -ve first episode psychosis and antioxidant effects of risperidone. <i>Journal of Psychiatric Research</i> , 2015, 68, 210-216.	3.1	51
12	Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. <i>Translational Psychiatry</i> , 2018, 8, 174.	4.8	49
13	Effects of depression on the cytokine profile in drug na ⁺ -ve first-episode psychosis. <i>Schizophrenia Research</i> , 2015, 164, 53-58.	2.0	48
14	Oxidative and nitrosative stress biomarkers in chronic schizophrenia. <i>Psychiatry Research</i> , 2017, 253, 43-48.	3.3	43
15	Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 336-339.	1.7	42
16	Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression. <i>NeuroImmunoModulation</i> , 2014, 21, 131-139.	1.8	40
17	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. <i>Molecular Neurobiology</i> , 2016, 53, 2927-2935.	4.0	40
18	Association of biomarkers and depressive symptoms in schizophrenia. <i>Neuroscience Letters</i> , 2011, 505, 282-285.	2.1	38

#	ARTICLE	IF	CITATIONS
19	Changes in gene expression and methylation in the blood of patients with first-episode psychosis. Schizophrenia Research, 2014, 159, 358-364.	2.0	35
20	Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis. Schizophrenia Research, 2015, 166, 225-230.	2.0	34
21	Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. Journal of Psychiatric Research, 2013, 47, 467-471.	3.1	32
22	Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. Metabolic Brain Disease, 2017, 32, 1003-1016.	2.9	32
23	Impairments in Peripheral Blood T Effector and T Regulatory Lymphocytes in Bipolar Disorder Are Associated with Staging of Illness and Anti-cytomegalovirus IgG Levels. Molecular Neurobiology, 2021, 58, 229-242.	4.0	29
24	Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis. Journal of Psychiatric Research, 2015, 71, 89-96.	3.1	28
25	Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis. Translational Psychiatry, 2016, 6, e908-e908.	4.8	26
26	Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls. Revista Brasileira De Psiquiatria, 2017, 39, 302-308.	1.7	26
27	Shorter leukocyte telomere length in patients at ultra high risk for psychosis. European Neuropsychopharmacology, 2017, 27, 538-542.	0.7	25
28	Leukocyte telomere length variation in different stages of schizophrenia. Journal of Psychiatric Research, 2018, 96, 218-223.	3.1	25
29	Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis. European Neuropsychopharmacology, 2015, 25, 2416-2425.	0.7	23
30	Accessing Gene Expression in Treatment-Resistant Schizophrenia. Molecular Neurobiology, 2018, 55, 7000-7008.	4.0	23
31	Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia. Psychiatry Research, 2015, 229, 702-707.	3.3	22
32	First Episode Psychosis and Schizophrenia Are Systemic Neuro-Immune Disorders Triggered by a Biotic Stimulus in Individuals with Reduced Immune Regulation and Neuroprotection. Cells, 2021, 10, 2929.	4.1	21
33	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. Revista Brasileira De Psiquiatria, 2015, 37, 280-288.	1.7	19
34	Investigating brain structural patterns in first episode psychosis and schizophrenia using MRI and a machine learning approach. Psychiatry Research - Neuroimaging, 2018, 275, 14-20.	1.8	18
35	Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. Communications Biology, 2018, 1, 163.	4.4	17
36	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. Psychiatry Research - Neuroimaging, 2015, 234, 84-89.	1.8	16

#	ARTICLE	IF	CITATIONS
37	Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages. NPJ Schizophrenia, 2019, 5, 5.	3.6	16
38	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. Schizophrenia Research, 2020, 218, 195-200.	2.0	16
39	Hair cortisol in drug-naïve first-episode individuals with psychosis. Revista Brasileira De Psiquiatria, 2016, 38, 11-16.	1.7	15
40	PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia. PLoS ONE, 2014, 9, e87686.	2.5	14
41	Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls. World Journal of Biological Psychiatry, 2015, 16, 441-446.	2.6	14
42	Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia. Schizophrenia Research, 2019, 208, 202-208.	2.0	14
43	Pharmacological and Psychosocial Management of Mental, Neurological and Substance Use Disorders in Low- and Middle-Income Countries: Issues and Current Strategies. Drugs, 2013, 73, 1549-1568.	10.9	13
44	Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: A follow-up study in antipsychotic-naïve patients with first-episode psychosis. Journal of Psychiatric Research, 2014, 56, 130-136.	3.1	13
45	Psychosis in Machado-Joseph Disease: Clinical Correlates, Pathophysiological Discussion, and Functional Brain Imaging. Expanding the Cerebellar Cognitive Affective Syndrome. Cerebellum, 2016, 15, 483-490.	2.5	13
46	New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage. Comprehensive Psychiatry, 2017, 73, 93-96.	3.1	13
47	BDNF in antipsychotic naive first episode psychosis: Effects of risperidone and the immune-inflammatory response system. Journal of Psychiatric Research, 2021, 141, 206-213.	3.1	12
48	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. Expert Review of Neurotherapeutics, 2013, 13, 795-807.	2.8	11
49	Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment. Psychiatry Research, 2013, 210, 1290-1292.	3.3	11
50	Pharmacological treatment of schizophrenia. International Review of Psychiatry, 2012, 24, 489-498.	2.8	10
51	Schneider's first-rank symptoms as predictors of remission in antipsychotic-naïve first-episode psychosis. Revista Brasileira De Psiquiatria, 2020, 42, 22-26.	1.7	10
52	Structural brain abnormalities in schizophrenia in adverse environments: examining the effect of poverty and violence in six Latin American cities. British Journal of Psychiatry, 2021, 218, 112-118.	2.8	10
53	Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness. Clinical Schizophrenia and Related Psychoses, 2017, 11, 151-155.	1.4	10
54	Omics-based depression and inflammation research. Revista Brasileira De Psiquiatria, 2015, 37, 1-2.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 677-683.	1.7	7
56	LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort. <i>Epigenomics</i> , 2020, 12, 1041-1051.	2.1	7
57	Aging biological markers in a cohort of antipsychotic-naïve first-episode psychosis patients. <i>Psychoneuroendocrinology</i> , 2021, 132, 105350.	2.7	7
58	A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 721-730.	2.1	6
59	Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial. <i>Trials</i> , 2019, 20, 199.	1.6	5
60	Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals. <i>Schizophrenia Research: Cognition</i> , 2019, 16, 12-16.	1.3	5
61	DGCR2 influences cortical thickness through a mechanism independent of schizophrenia pathogenesis. <i>Psychiatry Research</i> , 2019, 274, 391-394.	3.3	4
62	Is treatment-resistant schizophrenia associated with distinct neurobiological callosal connectivity abnormalities?. <i>CNS Spectrums</i> , 2021, 26, 545-549.	1.2	4
63	Patients with Schizophrenia Undergoing Gastric Bypass Surgery: a Case Series Study. <i>Obesity Surgery</i> , 2020, 30, 3813-3821.	2.1	4
64	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. <i>Schizophrenia Research</i> , 2021, .	2.0	4
65	Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia. <i>Molecular Neurobiology</i> , 2022, 59, 3170-3182.	4.0	4
66	What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS. <i>Schizophrenia Research</i> , 2014, 158, 277-278.	2.0	3
67	Blood gene expression changes after Risperidone treatment in an antipsychotic-naïve cohort of first episode of psychosis patients. <i>Schizophrenia Research</i> , 2020, 220, 285-286.	2.0	3
68	Longitudinal invariance of the positive and negative syndrome scale negative dimension in antipsychotic naïve first-episode schizophrenia. <i>Microbial Biotechnology</i> , 2022, 16, 581-586.	1.7	3
69	Clozapine-induced hepatotoxicity: A life threatening situation. <i>Schizophrenia Research</i> , 2021, 235, 3-4.	2.0	3
70	Esketamine for Postpartum Suicidality. <i>Biological Psychiatry</i> , 2021, 89, e35-e36.	1.3	2
71	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. <i>Trends in Psychiatry and Psychotherapy</i> , 2013, 35, 62-75.	0.8	1
72	How challenging is to manage agitated patients?. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 277-278.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Unraveling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia. Nordic Journal of Psychiatry, 2022, 76, 559-564.	1.3	1
74	Gene Expression Alterations Related To Mania And Psychotic Symptoms In Peripheral Blood of Patients with A First Episode of Psychosis. European Neuropsychopharmacology, 2017, 27, S403-S404.	0.7	0
75	GENOME-WIDE DNA METHYLATION ANALYSIS IN A LONGITUDINAL COHORT OF ANTIPSYCHOTIC-NAIVE FIRST EPISODE OF PSYCHOSIS PATIENTS. European Neuropsychopharmacology, 2019, 29, S1007-S1008.	0.7	0